Dr. Sophie Dessureault, MD, PhD

Dr. Dessureault practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Dessureault's NPI, 1225069313, was assigned on July 6, 2006. Dr. Dessureault graduated from Dalhousie University Faculty of Medicine in 1990. Dr. Dessureault holds Florida license ME87239.

Dr. Dessureault's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Dessureault's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Dessureault is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Dessureault to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dessureault practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Dessureault's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Dessureault is board certified in surgery by the American Board of Surgery. Dr. Dessureault is licensed in Florida.

Dmand AI lists cirrhosis of the liver among the conditions Dr. Dessureault treats.

CMS data shows 115 Medicare services from Dr. Dessureault across 3 procedure codes in 2024, for 82 Medicare patients. Medicare paid $10,842 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 82 Medicare patients who saw Dr. Dessureault in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dessureault's median patient age at 66, with 58% women.

In 2024, Dr. Dessureault wrote 88 Medicare Part D claims for 32 patients. 92% of them were for generic drugs. CMS names the drug for 21 of them, across 1 drug with 11 or more claims each, at $1,522 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Dessureault for performance year 2024, reported as part of a group. Dr. Dessureault accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dessureault as offering telehealth. CMS counts 45 procedures of skin biopsy by Dr. Dessureault, more than 68% of the clinicians it reports for that procedure.

Dmand AI links 59 papers to Dr. Dessureault, published from 2005 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Chemotherapy, Cancer, Regional Perfusion, Cytoreduction Surgical Procedures and Lymph Nodes. Dr. Dessureault has published most often in Ann Surg Oncol. Dr. Dessureault's most frequent co-authors are Seth Ian Felder, MD, Iman Imanirad, MD and Sean Patrick Dineen, MD.

Dmand AI links Dr. Dessureault to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Lymphoma, Mantle-Cell, Melanoma and Lymphoma, Non-Hodgkin. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

Dr. Dessureault graduated from Dalhousie University Faculty of Medicine in 1990. Dr. Dessureault is a member of ASCO.

Dr. Dessureault is in network with 8 carriers, including United Healthcare, Humana and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.